Graham Walmsley

Director/Board Member at OLEMA PHARMACEUTICALS, INC.

Net worth: - $ as of 30/08/2026

39 year

80 connections

Health Technology

Finance

Consumer Services

Profile

Dr. Graham G.
Walmsley is an Independent Director at Olema Pharmaceuticals, Inc., a Managing Partner at Logos Capital Fund LLP, a General Partner at Logos Global Management LP and a Managing Partner at Logos Capital LLC /Ca/.
He is on the Board of Directors at Olema Pharmaceuticals, Inc. and ALX Oncology, Inc. Dr. Walmsley was previously employed as an Independent Director by Lifesci Acquisition II Corp., an Independent Director by ALX Oncology Holdings, Inc., an Independent Director by Akero Therapeutics, Inc., a Head-Business Development by Pipeline Therapeutics, Inc., a Head-Business Development by Jecure Therapeutics, Inc., and a Principal by Versant Venture Management LLC.
He also served on the board at Science 37 Holdings, Inc. He received his undergraduate degree from the University of California, Berkeley and a doctorate degree from Stanford University School of Medicine.

Known holdings in public companies

Company	Date	Number of shares	Valuation	Valuation date
OLEMA PHARMACEUTICALS, INC. -.--%	17/06/2026	0 ( -.--% )	- $	30/08/2026

Graham Walmsley active positions

Companies	Position	Start
OLEMA PHARMACEUTICALS, INC.	Director/Board Member	29/02/2020
Logos Capital Fund LLP Logos Capital Fund LLP Investment Trusts/Mutual FundsMiscellaneous Functions as a pooled investment fund	Founder	31/07/2019
ALX Oncology, Inc. ALX Oncology, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage immuno-oncology company which develops therapies for cancers	Director/Board Member	31/01/2020
Logos Global Management LP Logos Global Management LP Investment ManagersFinance Logos seeks to generate superior risk adjusted returns. The firm intends to deliver capital appreciation for the Public Funds primarily through a mix of long and short investment strategies, including a number of hedging strategies to preserve capital and manage risk exposure. Most of the Public Funds’ assets are expected to be invested on a global basis in publicly traded equity securities in the healthcare and life sciences industries.	Founder	28/02/2019

All active positions of Graham Walmsley

Former positions of Graham Walmsley

Companies	Position	End
AKERO THERAPEUTICS, INC.	Director/Board Member	08/12/2025
ALX ONCOLOGY HOLDINGS INC.	Director/Board Member	31/07/2021
Versant Venture Management LLC Versant Venture Management LLC Investment ManagersFinance Versant Ventures invests in biotechnology companies located globally. The firm participates in early and later stage capital requirements.	Private Equity Investor	31/07/2019
CONTINEUM THERAPEUTICS, INC.	Corporate Officer/Principal	30/11/2018
Jecure Therapeutics, Inc. Jecure Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Engages in research of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) and liver fibrosis	Corporate Officer/Principal	31/10/2018

See the detail of Graham Walmsley's experience

Training of Graham Walmsley

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Graham Walmsley's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	13
University of California, Berkeley University of California, Berkeley Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Versant Venture Management LLC Versant Venture Management LLC Investment ManagersFinance Versant Ventures invests in biotechnology companies located globally. The firm participates in early and later stage capital requirements.	Finance
Stanford University School of Medicine Stanford University School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Logos Capital Fund LLP Logos Capital Fund LLP Investment Trusts/Mutual FundsMiscellaneous Functions as a pooled investment fund	Miscellaneous
Jecure Therapeutics, Inc. Jecure Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Engages in research of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) and liver fibrosis	Commercial Services
Akero Therapeutics, Inc. Akero Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops therapies for patients with metabolic diseases	Health Technology
Olema Pharmaceuticals, Inc. Olema Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures drugs for the treatment & prevention of estrogen receptor positive breast cancer	Health Technology
ALX Oncology, Inc. ALX Oncology, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage immuno-oncology company which develops therapies for cancers	Health Technology
Logos Global Management LP Logos Global Management LP Investment ManagersFinance Logos seeks to generate superior risk adjusted returns. The firm intends to deliver capital appreciation for the Public Funds primarily through a mix of long and short investment strategies, including a number of hedging strategies to preserve capital and manage risk exposure. Most of the Public Funds’ assets are expected to be invested on a global basis in publicly traded equity securities in the healthcare and life sciences industries.	Finance
Pipeline Therapeutics, Inc. Pipeline Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical stage biopharmaceutical company that develops novel, oral small molecule therapies for neuroscience, inflammation and immunology indications	Health Technology
ALX Oncology Holdings, Inc. ALX Oncology Holdings, Inc. BiotechnologyHealth Technology Operates as clinical stage immuno-oncology company, which develops therapies for cancer	Health Technology
Lifesci Acquisition II Corp. Lifesci Acquisition II Corp. Financial ConglomeratesFinance Operates as a blank check company	Finance
Science 37 Holdings, Inc. Science 37 Holdings, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a clinical research company	Commercial Services